CTE 2021 Q&A

  • March 9, 2022

Raphaële Mary, one of TriRadial's Vendor Outsourcing Management experts, along with Alexandra Kemmer-Brück, Senior Director of Clinical Operations at BioNTech SE, discuss Establishing Fit-for-Purpose Vendor Oversight for Emerging Biopharma during the Clinical Trials Europe conference.

During the Q&A, Raphaële expands on Alexandra's answer to the question, “How do you ensure you get the A Team when you are a small BioPharma?” by outlining several core tenets of TriRadial's approach to Vendor Oversight.

TriRadial focuses on establishing structured frameworks to enable collaborative and scalable relationships.

 

 

 

LEAVE A COMMENT

More from the Blog

How FDA’s publishing of Complete Response Letters impacts your clinical risk mitigation strategy

July 28, 2025
Under its new leadership, FDA has started publishing its Complete Response Letters (CRLs) for public consumption...

What does the move to QMSR and the implications of ICHE6(R3) mean for clinical stage biotechs?

June 25, 2025
In less than a year, two major updates to Quality regulations will go into effect in the European Union and United...

How to Navigate FDA’s New Priorities

July 11, 2025
Recently the United States Commissioner of Food and Drugs, Martin Makary, MD. MPH, and the Director of the Center for...